ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Late-Breaking 2019"

  • Abstract Number: L05 • 2019 ACR/ARP Annual Meeting

    Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA

    Benjamin Hsu1, Jennifer Visich 2, Mark Genovese 3, Kimberly Walter 2, Mahru An 4, Remi-Martin Laberge 4 and Jamie Dananberg 4, 1Unity Biotechnology, Brisbane, 2Unity Biotechnology, Brisbane, California, 3Stanford University, Stanford, CA, 4Unity Biotechnology, Brisbane, CA

    Background/Purpose: A non-drug biomarker study showed senescent cell (SnC) burden in OA synovial tissue to correlate with disease severity, inflammation, and knee pain (C. Yohn,…
  • Abstract Number: L21 • 2019 ACR/ARP Annual Meeting

    Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study

    Atul Deodhar1, Ricardo Blanco 2, Eva Dokoupilova 3, Marleen van de Sande 4, Stephen Hall 5, Anna Wiksten 6, Brian Porter 7, Hanno Richards 6, Sibylle Haemmerle 6 and Jürgen Braun 8, 1Oregon Health & Science University, Portland, OR, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3MEDICAL PLUS s.r.o., Uherske Hradiste; University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Brno, Czech Republic, 4Amsterdam Rheumatology and immunology Center, Department of Rheumatology and Clinical Immunology, Amsterdam UMC /University of Amsterdam, Amsterdam, Netherlands, 5Monash University, Melbourne, Australia, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany

    Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) are considered part of the spectrum of axSpA. Patients (pts) are classified as nr-axSpA due to…
  • Abstract Number: L06 • 2019 ACR/ARP Annual Meeting

    Interferon-gamma (IFN-γ) Neutralization with Emapalumab and Time to Response in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (s-JIA) who failed High-Dose Glucocorticoids

    Fabrizio De Benedetti1, Paul Brogan 2, Alexei A. Grom 3, Pierre Quartier 4, Rayfel Schneider 5, Jordi Antón 6, Claudia Bracaglia 7, Manuela Pardeo 8, Giulia Marucci 8, Emanuela Sacco 9, Despina Eleftheriou 10, Charalampia Papadopoulou 11, Philippe Jacqmin 12, maria ballabio 13 and Cristina de Min 13, 1Bambino Gesù Children's Hospital, Rome, Italy, 2Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, 3Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Necker Hospital, Paris, France, 5Hospital for Sick Children, Toronto, ON, Canada, 6Hospital Sant Joan de Déu, Barcelona, Spain, 7Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 8Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 9Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, 10UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Infection, Immunology, and Rheumatology section,, london, United Kingdom, 11UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Infection, Immunology, and Rheumatology section, london, United Kingdom, 12MnS, Dinant, Belgium, 13Sobi AG, basel, Switzerland

    Background/Purpose: MAS is a severe complication of rheumatic diseases, most frequently sJIA and adult-onset Still’s disease. It is characterized by fever, hepatosplenomegaly, liver dysfunction, cytopenias,…
  • Abstract Number: L22 • 2019 ACR/ARP Annual Meeting

    Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study

    Hermine Brunner1, Olga Synoverska 2, Tracy Ting 3, Carlos Abud Mendoza 2, Alberto Spindler 2, Yulia Vyzhga 2, Katherine Marzan 3, Vladimir Keltsev 2, Irit Tirosh 2, Lisa Imundo 3, Rita Jerath 3, Daniel Kingsbury 3, Betul Sozeri 2, Sheetal Vora 3, Sampath Prahalad 3, Elena Zholobova 2, Yonatan Butbul Aviel 2, Vyacheslav Chasnyk 2, Melissa Lerman 3, Kabita Nanda 3, Heinrike Schmeling 3, Heather Tory 3, Yosef Uziel 2, Diego Oscar Viola 2, Holly Posner 4, Keith Kanik 5, Ann Wouters 4, Cheng Chang 5, Richard Zhang 4, Irina Lazariciu 6, Ming-Ann Hsu 5, Ricardo Suehiro 7, Alberto Martini 2, Daniel J. Lovell 3 and Nicolino Ruperto 8, 1PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 2PRINTO, Istituto Giannina Gaslini, Genova, Italy, 3PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 4Pfizer Inc, New York, New York, 5Pfizer Inc, Groton, Connecticut, 6IQVIA, Montreal, Quebec, Canada, 7Pfizer Inc, Collegeville, Pennsylvania, 8PRINTO, Istituto Giannina Gaslini, Genoa, Italy

    Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. Here we assess the efficacy and safety of tofacitinib in patients (pts)…
  • Abstract Number: L07 • 2019 ACR/ARP Annual Meeting

    A Serum Proteomic Signature Defines Transition from the Preclinical State to Rheumatoid Arthritis

    Liam O'Neil1, Victor Spicer 1, Irene Smolik 1, Xiaobo Meng 1, John Wilkins 1 and Hani El-Gabalawy 2, 1University of Manitoba, Winnipeg, Canada, 2University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are currently the primary biomarker for identifying individuals at increased risk for future RA development. However, we have recently shown…
  • Abstract Number: L08 • 2019 ACR/ARP Annual Meeting

    Tapering of Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients in Sustained Remission: Results from a Randomized Controlled Trial

    Siri Lillegraven1, Nina Sundlisater 2, Anna-Birgitte Aga 3, Joe Sexton 1, Inge Christoffer Olsen 4, Hallvard Fremstad 5, Cristina Spada 6, Tor Magne Madland 7, Christian Høili 8, Gunnstein Bakland 9, Åse Lexberg 10, Inger Johanne Widding Hansen 11, Inger Myrnes Hansen 12, Hilde Haukeland 13, Maud-Kristine Aga Ljoså 14, Ellen Moholt 15, Till Uhlig 16, Daniel Solomon 17, Désirée van der Heijde 18, Tore Kvien 16 and Espen A Haavardsholm 15, 1Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 2Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, 3Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, 4Oslo University Hospital, Oslo, Norway, 5Ålesund Hospital, Helse Møre og Romsdal, Ålesund, Norway, 6Lillehammer Hosptial for Rheumatic Diseases, Lillehammer, Norway, 7Haukeland University Hospital, Bergen, Norway, 8Hospital Østfold HF, Moss, Norway, 9University Hospital of North Norway, Tromsø, Norway, 10Drammen Hospital, Vestre Viken HF, Drammen, Norway, 11Sørlandet Hospital HF, Kristiansand, Norway, 12Helgelandssykehuset Mo i Rana, Mo i Rana, Norway, 13Martina Hansens Hospital, Bærum, Norway, 14Ålesund Hospital Helse Møre og Romsdal HF, Ålesund, Norway, 15Diakonhjemmet Hospital, Oslo, Norway, 16Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 17Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, 18Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Sustained remission is the goal of rheumatoid arthritis (RA) care, and more patients reach and maintain this state on conventional synthetic disease modifying anti-rheumatic…
  • Abstract Number: L09 • 2019 ACR/ARP Annual Meeting

    A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial

    Merete Lund Hetland1, Espen A Haavardsholm 2, Anna Rudin 3, Dan Nordström 4, Mike Nurmohamed 5, Bjorn Gudbjornsson 6, Jon Lampa 7, Kim Hørslev-Petersen 8, Till Uhlig 9, Gerdur Grondal 10, Mikkel Østergaard 11, Marte Heiberg 2, Jos Twisk 12, Kristina Lend 7, Simon Krabbe 13, Joakim Lindqvist 7, Anna-Karin Ekwall 14, Kathrine Lederballe Grøn 15, Meliha Kapetanovic 16, Francesca Faustini 7, Riitta Tuompo 17, Tove Lorenzen 18, Giovanni Cagnotto 19, Eva Baecklund 20, Oliver Hendricks 21, Daisy Vedder 22, Tuulikki Sokka-isler 23, Tomas Husmark 24, Maud-Kristine Aga Ljoså 25, Eli Brodin 26, Torkell Ellingsen 27, Annika Söderbergh 28, Milad Rizk 29, Åsa Reckner 30, Line Uhrenholt 31, Per Larsson 32, Soeren Just 33, David Stevens 34, Trine Laurberg 35, Gunnstein Bakland 36, Inge Christoffer Olsen 37, Ronald van Vollenhoven 38 and The NORD-STAR Study Group 39, 1DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 2Diakonhjemmet Hospital, Oslo, Norway, 3Dept Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden, 4Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, 5Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands, 6Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 7Karolinska Institutet, Stockholm, Sweden, 8Department of Rheumatology, King Christian X's Hospital for Rheumatic Diseases Graasten, Denmark, Graasten, Denmark, 9Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 10Department of Rheumatology, Landspitali and Centre for Rheumatology Research, Landspitali, Reykjavík, Iceland, 11Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, 12Department of Epidemiology and Biostatistics, Amsterdam UMC, Amsterdam, Netherlands, 13Rigshospitalet, København, Denmark, 14University of Gothenburg, Kullavik, Sweden, 15Rigshospitalt Glostrup, Glostrup, Denmark, 16Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, 17Helsinki University Hospital, Helsinki, Finland, 18Reumatologi, Regionshospitalet Silkeborg, Kolding, Denmark, 19Lund University, Malmö, Sweden, 20Uppsala University, Uppsala, Sweden, 21Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, 22Amsterdam Rheumatology & immunology Center / Reade, Amsterdam, Netherlands, 23Jyvaskyla Central Hospital, Jyvaskyla, Finland, 24Rheumatology Clinic, Falun, Sweden, 25Ålesund Hospital Helse Møre og Romsdal HF, Ålesund, Norway, 26Haukeland University Hospital, Bergen, Norway, 27Department of Rheumatology, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark, 28Örebro University Hospital, Ôrebro, Sweden, 29Västmanlands Hospital, Västerås, Sweden, 30Rheumatology Department, Linkoping, Sweden, 31Aalborg Universitetshospital, Aalborg, Denmark, 32Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, 33Odense University Hospital, Odense, 34St. Olav's University Hospital, Trondheim, Norway, 35Aarhus University Hospital, Aarhus, Denmark, 36University Hospital of North Norway, Tromsø, Norway, 37Oslo University Hospital, Oslo, Norway, 38Amsterdam Rheumatology and immunology Center, Netherlands., Amsterdam, Netherlands, 39Site investigators in all participating countries, Stockholm, Sweden

    Background/Purpose: The optimal first-line treatment of patients (pts) with early rheumatoid arthritis (RA) is yet to be established. The primary aim was to assess and…
  • Abstract Number: L10 • 2019 ACR/ARP Annual Meeting

    Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis

    Roberta Gualtierotti1, Francesca Ingegnoli 2, Massimo Boscolo 3, Samantha Griffini 3, Elena Grovetti 4 and Massimo Cugno 5, 1Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Lombardia, Italy, 2UOC Reumatologia Clinica, ASST Pini-CTO, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy, 3Medicina Interna, Ospedale Maggiore Policlinico, IRCCS Fondazione Ca' Granda Milano, Italy, Milan, 4Medicina Interna, Ospedale Maggiore Policlinico, IRCCS Fondazione Ca' Granda Milano, Milan, 5Medicina Interna, Ospedale Maggiore Policlinico, IRCCS Fondazione Ca' Granda Milano, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease associated with a prothrombotic state. Tocilizumab, an interleukin-6 receptor inhibitor, is highly effective in controlling…
  • Abstract Number: L11 • 2019 ACR/ARP Annual Meeting

    Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Thomas W.J. Huizinga 4, Gustavo Citera 5, Clifton Bingham 6, Subhashis Banerjee 7, Benjamin Soule 8, Marleen Nys 9, Sean Connolly 10, Robert Wong 10, Kuan-Hsiang Gary Huang 7 and Roy Fleischmann 11, 1University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, 4Leiden University Medical Center, Leiden, Netherlands, 5Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 6Johns Hopkins University, Baltimore, 7Bristol-Myers Squibb, Princeton, NJ, 8Bristol-Myers Squibb, Princeton, New Jersey, 9Bristol-Myers Squibb, Braine L'Alleud, Belgium, 10Bristol-Myers Squibb, Princeton, 11Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Although EULAR/ACR guidelines suggest tapering biologics following sustained remission in patients (pts) with RA, specific de-escalation (DE) regimens are not fully defined. The Phase…
  • Abstract Number: L12 • 2019 ACR/ARP Annual Meeting

    Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study

    Evgeniy Nasonov 1, Saeed Fatenejad 2, Elena Korneva 3, Diana Krechikova 4, Alexey Maslyansky 5, Tatyana Plaksina 6, Marina Stanislav 7, Rumen Stoilov 8, Tamara Tyabut 9, Sergey Yakushin 10, Elena Zonova 11 and Mark Genovese12, 1FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, 2SFC Medica, Charlotte, North Carolina, 3R-Pharm, Moscow, Russia, 4Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways, Smolensk, Russia, 5SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation, St-Petersburg, Russia, 6SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", N.Novgorod, Russia, 7V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, 8UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, 9Belarusian Medical Academy of Postgraduate Education, City Clinical Hospital N1, Minsk, Belarus, 10Ryazan State Medical University, Ryazan, Russia, 11Novosibirsk State Medical University, State Clinical Polyclinic 1, Novosibirsk, Russia, 12Stanford University, Stanford, CA

    Background/Purpose: Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 1, 2. Here we present the results of the first phase III study of…
  • Abstract Number: L13 • 2019 ACR/ARP Annual Meeting

    Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Philip J. Mease1, Proton Rahman 2, Alice B. Gottlieb 3, Elizabeth Hsia 4, Alexa Kollmeier 5, Xie Xu 6, Ramanand Subramanian 5, Prasheen Agarwal 5, Shihong Sheng 5, Bei Zhou 5, Désirée van der Heijde 7 and Iain McInnes 8, 1Swedish Medical Center and University of Washington, Seattle, Washington, 2Memorial University of Newfoundland, Newfoundland, Canada, 3Icahn School of Medicine at Mt Sinai, NY, NY, New York, New York, 4Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, Pennsylvania, 5Janssen Research & Development, LLC, Spring House, Pennsylvania, 6Janssen Research & Development, LLC, Spring House, 7Leiden University Medical Center, Leiden, Netherlands, 8Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…
  • Abstract Number: L14 • 2019 ACR/ARP Annual Meeting

    Tofacitinib as Monotherapy Following Methotrexate Withdrawal in Patients with Psoriatic Arthritis Previously Treated with Open-label Tofacitinib + Methotrexate: A Randomized, Placebo-controlled Sub-study of OPAL Balance

    Peter Nash1, Laura Coates 2, Philip J. Mease 3, Alan Kivitz 4, Dafna Gladman 5, Frank Behrens 6, James C Wei 7, Dona Fleishaker 8, Joseph Wu 8, Cunshan Wang 8, Ana Romero 9, Lara Fallon 10, Ming-Ann Hsu 8 and Keith Kanik 8, 1Griffith University, Brisbane, Queensland, Australia, 2University of Oxford, Oxford, United Kingdom, 3Swedish Medical Center and University of Washington, Seattle, Washington, 4Altoona Center for Clinical Research, Duncansville, 5University of Toronto, Toronto, Canada, 6CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, 7Chung Shan Medical University, Taichung City, Taiwan (Republic of China), 8Pfizer Inc, Groton, Connecticut, 9Pfizer Inc, Barcelona, Spain, 10Pfizer Inc, Montreal, Canada

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Tofacitinib monotherapy has not been previously studied in PsA. This sub-study of…
  • Abstract Number: L15 • 2019 ACR/ARP Annual Meeting

    Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial

    David Isenberg1, Richard Furie 2, Nicholas Jones 3, Pascal Guibord 4, Joshua Galanter 5, Chin Lee 3, Anna McGregor 3, Balazs Toth 3, Julie Rae 3, Olivia Hwang 3, Pedro Miranda 6, Viviane de Souza 7, Juan Jaller-Raad 8, Anna Maura Fernandes 9, Rodrigo Garcia Salinas 10, Leslie Chinn 3, Michael Townsend 11, Alyssa Morimoto 3 and Katie Tuckwell 12, 1University College London, London, United Kingdom, 2Northwell Health, Great Neck, NY, 3Genentech, Inc., South San Francisco, California, 4Hoffmann-La Roche Limited, Mississauga, Canada, 5Genentech, Inc., SOUTH SAN FRANCISCO, 6Centro Estudios Reumatologicos, Santiago, Chile, 7Centro Mineiro de Pesquisas, Juiz de Fora, Minas Gerais, Brazil, 8Centro de Reumatologia y Ortopedia, Cimedical, Barranquilla, Colombia, 9Mario Covas Hospital, Santo Andre, Sao Paulo, Brazil, 10Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, 11Genentech, Inc., San Fransisco, 12Genentech, Inc., South San Francisco, CA

    Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an oral, non-covalent, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK) in clinical development for autoimmune diseases. The efficacy,…
  • Abstract Number: L16 • 2019 ACR/ARP Annual Meeting

    GLCCI1 Polymorphism Is Associated with Prednisone Response in Giant Cell Arteritis: A Multicenter Prospective Study

    Samuel Deshayes1, Venceslas Bourdin 2, Christian Creveuil 3, Jonathan Boutemy 1, Eric Liozon 4, Xavier Kyndt 5, Laurent Sailler 6, Grégory Pugnet 6, Hubert de Boysson 1, Eric Hachulla 7, Marc André 8, Julie Magnant 9, Jacques Boddaert 10, Olivier Fain 11, Arsène Mékinian 11, Mohamed Hamidou 12, Loïc Guillevin 13, Cédric Landron 14, Isabelle Marie 15, Yannick Chène 3, Laurent Becquemont 16, Céline Verstuyft 2 and Boris Bienvenu 17, 1Department of Internal Medicine, Caen University Hospital, Caen, France, 2INSERM UMR_S1178, Medicine Faculty, CESP, Paris-Sud University, Le Kremlin Bicêtre, Paris, France, 3Biomedical Reserch Unit, Caen University Hospital, Caen, France, 4Department of Internal Medicine and Clinical Immunology, Limoges University Hospital, Limoges, France, 5Department of Internal Medicine and Nephrology, Valenciennes Hospital, Valenciennes, France, 6Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, 7Department of Internal Medicine and Clinical Immunology, Lille University Hospital, Lille, France, 8Department of Internal Medicine, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, 9Department of Internal Medicine, Tours University Hospital, Tours, France, 10Department of Geriatrics, Pitié-Salpêtrière-Charles Foix University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, 11Department of Internal Medicine, Saint Antoine University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, 12Department of Internal Medicine, Nantes University Hospital, Nantes, France, 13Department of Internal Medicine, Cochin University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, 14Department of Internal Medicine, Poitiers University Hospital, Poitiers, France, 15Department of Internal Medicine, Rouen University Hospital, Rouen, France, 16INSERM UMR_S1178, Medicine Faculty, CESP, Paris-Sud University, Le Kremlin Bicêtre, Le Kremblin Bicêtre, France, 17Department of Internal Medicine, Saint Joseph Hospital, Marseille, France

    Background/Purpose: Giant cell arteritis (GCA) is the most common cause of primary vasculitis in adults. Corticosteroids are the cornerstone of the treatment. However, approximately 50%…
  • Abstract Number: L01 • 2019 ACR/ARP Annual Meeting

    Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study

    Yinzhu Jin 1, Hemin Lee 1, Moa Lee 2, Joan Landon 3, Joseph Merola 4, Rishi Desai 5 and Seoyoung C. Kim1, 1Brigham and Women's Hospital and Harvard Medical School, Boston, 2University of North Carolina Chapel Hill, Chapel Hill, North Carolina, 3Brigham and Women's Hospital, Boston, Massachusetts, 4Harvard Medical School, Brigham and Women's Hospital, Boston, 5Brigham and Women's hospital, Boston

    Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA)…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology